Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.67 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 6/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 4/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745582 | 0.97 | CHRM1 (0.67) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL3635266 | 0.94 | OPRM1 (0.69) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL3665754 | 0.92 | CYP2D6 (0.57) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL3666221 | 0.89 | CYP2D6 (0.57) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL3806337 | 0.88 | OPRM1 (0.70) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL24709114 | 0.85 | CYP2D6 (0.74) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL31000422 | 0.85 | CYP2D6 (0.74) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL3639398 | 0.85 | OPRM1 (0.67) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL5984495 | 0.85 | CYP2D6 (0.85) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 | |
| SCHEMBL11290346 | 0.85 | CYP2D6 (0.70) | CYP2D6CYP2C9OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | claimed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | claimed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2010-11-18 | — | — | US | disclosed |
| WO-2008146172-A2 | COMPOUNDS WITH ANTIPARASITIC ACTIVITY, APPLICATIONS THEREOF TO THE TREATMENT OF INFECTIOUS DISEASES CAUSED BY APICOMPLEXANS | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-12-04 | — | — | WO | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292214-A1 | Compounds with Antiparasitic Activity, Applications thereof to the Treatment of Infectious Diseases Caused by Apicomplexans | ABCB11, TPP1, ABCB1 | CYP2D6 873/4885CYP2C9 657/4885OPRM1 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.